Trinity St James’s Cancer Institute, Ireland’s first OECI-accredited comprehensive cancer centre, unites research, care and education to advance cancer care.
Having achieved the accreditation as the first Comprehensive Cancer Centre in Ireland we hope we @CancerInstIRE can support national efforts to contribute to a decrease in cancer incidence and mortality in Ireland, and represent as a standard bearer for cancer care.
An outstanding initiative 👏 Supporting cancer nurses with high-quality education and simulation-based learning is vital to delivering excellent patient care. Well done to all involved @stjamesdublin@CancerInstIRE@TCD_SNM@AudreyOHalloran
📚 Day 5 of our Annual Foundation Course in Cancer Care & Haematology @stjamesdublin@CancerInstIRE. A fantastic programme for cancer nurses, concluded today with a simulation-based assessment @TCD_SNM — an invaluable opportunity to practice in a safe learning environment.
A landmark moment for pancreatic cancer, these findings highlight what transformative progress can look like. Congratulations to @EileenMOReilly & team @MSKCancerCenter advancing this research driving forward a new standard of care in a disease that has long needed breakthroughs
⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.
In a phase 3 study led by @EileenMOReilly and colleagues, patients receiving #daraxonrasib lived a median of 13.2 months compared with 6.7 months for those treated with chemotherapy.
"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease."
Learn more: https://t.co/1Lt18DdKMt
Exciting momentum in precision oncology, congratulations to @MSKCancerCenter@MichaelMayMD on advancing three first‑line metastatic KRAS inhibitor trials opening at @MSKCancerCenter in the coming weeks. A powerful signal of what’s ahead, with many more studies on the horizon.
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg
#ASCO26 | @ASCO
Great to hear this @RTERadio1 feature on cancer innovations @ASCO with @Dr_ClaireK Proud to see the first Public Patient Partnership Lead across @CancerInstIRE & @IrishCancerSoc mentioned, helping embed the patient voice at the heart of clinical care.
https://t.co/GAfrqhMHeb
What a moment! Incredible to be in the room for these practice-changing data in such a difficult-to-treat disease 🚀 Another RAS allele is now druggable. The promise of precision oncology—and a powerful reminder of what sustained drug development can achieve. @DavidHongMD#ASCO26
That’s a wrap on #ASCO2026! An excellent three days with some exciting breakthroughs presented, particularly in hard-to-treat cancers, and lots of learnings on patient advocacy.
We're taking home a real sense of hope for cancer patients globally.
🧬 Hormone receptors: oncology’s original #PrecisionOncology targets🌎 ESR1/AR alterations recur across diverse solid tumors in @AACRFoundationGENIE (>227,000 patients) 🎯 Time to rethink endocrine therapy as a tumor-agnostic strategy? 🎯 #ASCO26@VivekSubbiah 🙏@mraheelhashim
Our Head of Research, Dr Claire Kilty, is thrilled to touch down in Chicago for #ASCO2026 to represent the Irish Cancer Society and our partnership with Grainne Smith @stjamesdublin at the world's largest cancer conference.
Irish oncologist helps lead breakthrough pancreatic cancer pill. Major leap forward, incredible to see @CancerInstIRE External Advisory Board Chair Dr Eileen O’Reilly @EileenMOReilly & team @MSKCancerCenter leading the way in this game-changing step. https://t.co/Wed6waA4kE
One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results
I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore
@ASCO2026 Dr Ng, Dr Bergerot, Dr Su on the need for specialised services for young onset cancers - fertility, sexual health, psychosocial, financial, survivorship. The Young Onset Cancer Progamme in TSJCI @stjamesdublin in partnership with @IrishCancerSoc offers these services
Day 2 #ASCO2026 - surviving cancer isn’t the only thing that matters, how patients feel during treatment matters just as much. Using Patient Reported Outcomes to measure what actually matters to patients needs to be built into research and care. @stjamesdublin@IrishCancerSoc
Fascinating talk by Dr Eric Small, President of ASCO, on the importance of prioritising quality of life and patients' needs first. This became more apparent to him through personal experience. @stjamesdublin@IrishCancerSoc#PatientFirst#PatientPartnership
Getting very excited as #ASCO2026 is finally here. Everything is set to go at our exhibit where we will spend the next three days talking about our #PPI work with our partners, @IrishCancerSoc@stjamesdublin
Making the most of the bank holiday weekend? Stay #SunSmart slip on a t‑shirt, slop on SPF 30+, slap on a hat, seek shade & slide on sunglasses. Protect your skin while enjoying the sunshine! @CancerInstIRE@stjamesdublin@tcddublin@TrinityMed1